Baseline characteristics. Values are median (IQR) unless otherwise stated
| Demographics | n=203 |
| Female, n (%) | 125 (61.6) |
| Age, years | 54.1 (42.0, 62.9) |
| Symptom duration, months | 5.4 (2.8, 10.5) |
| Positive for ACPA, n (%) | 165 (81.3) |
| Positive for RF, n (%) | 140 (69.0) |
| Disease activity | |
| Disease activity score | 3.3 (2.6, 4.1) |
| Swollen joint count (0–44) | 9.0 (4.0, 14.0) |
| Ritchie Articular Index (0–78) | 6.0 (3.0, 12.0) |
| C reactive protein, mg/dL | 0.7 (0.3, 1.8) |
| Patient’s global assessment, VAS (0–10 mm)* | 4.9 (2.8, 6.9) |
| Physician’s global assessment, VAS (0–10 mm)* | 3.5 (2.3, 5.4) |
| PROMIS physical function (12.1–62.5) | 39.8 (33.3, 45.3) |
| Fatigue, VAS (0–10 mm)* | 3.7 (1.3, 6.3) |
| Ultrasound grey-scale score (0–96) | 19.0 (10.0, 28.0) |
| Ultrasound power Doppler score (0–96) | 7.0 (3.0, 14.0) |
| MRI RAMRIS synovitis (0–21) | 6.0 (4.0, 10.0) |
| MRI RAMRIS bone marrow oedema (0–75) | 1.0 (0.0, 6.0) |
| MRI RAMRIS tenosynovitis (0–42) | 5.0 (2.0, 10.0) |
*These variables were assessed on a VAS 0–100 mm, but converted to the more commonly used VAS 0–10 mm scale.
ACPA, anti-cyclic citrullinated peptides; PROMIS, Patient reported Outcome Measurement Information Score Short Form v1.0—Physical Function 20a (reported as T-scores); RAMRIS, Rheumatoid Arthritis MRI Scoring System; RF, rheumatoid factor; VAS, visual analogue scale.